Cellectar Biosciences Inc (NASDAQ:CLRB) has a beta value of 0.45 and has seen 0.52 million shares traded in the recent trading session. The company, currently valued at $13.19M, closed the recent trade at $0.29 per share which meant it lost -$0.01 on the day or -4.28% during that session. The CLRB stock price is -1110.34% off its 52-week high price of $3.51 and 24.14% above the 52-week low of $0.22. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.67 million shares traded. The 3-month trading volume is 1.17 million shares.
The consensus among analysts is that Cellectar Biosciences Inc (CLRB) is Buy stock at the moment, with a recommendation rating of 1.67. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.16.
Cellectar Biosciences Inc (NASDAQ:CLRB) trade information
Sporting -4.28% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CLRB stock price touched $0.29 or saw a rise of 4.95%. Year-to-date, Cellectar Biosciences Inc shares have moved -4.28%, while the 5-day performance has seen it change 2.51%. Over the past 30 days, the shares of Cellectar Biosciences Inc (NASDAQ:CLRB) have changed -24.70%. Short interest in the company has seen 2.22 million shares shorted with days to cover at 1.54.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 97.58% from the levels at last check today.. The projected low price target is $12.0 while the price target rests at a high of $12.0. In that case, then, we find that the latest price level in today’s session is -4037.93% off the targeted high while a plunge would see the stock gain -4037.93% from the levels at last check today..
Cellectar Biosciences Inc (CLRB) estimates and forecasts
The company’s shares have lost -86.24% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 40.27% over the past 5 years. Earnings growth for 2025 is a modest 47.54% while over the next 5 years, the company’s earnings are expected to increase by 16.51%.
CLRB Dividends
Cellectar Biosciences Inc is expected to release its next earnings report on 2025-Mar-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cellectar Biosciences Inc (NASDAQ:CLRB)’s Major holders
Insiders own 1.64% of the company shares, while shares held by institutions stand at 11.00% with a share float percentage of 11.18%. Investors are also buoyed by the number of investors in a company, with Cellectar Biosciences Inc having a total of 32.0 institutions that hold shares in the company. The top two institutional holders are AIGH CAPITAL MANAGEMENT LLC with over 3.04 million shares worth more than $6.86 million. As of 2024-06-30, AIGH CAPITAL MANAGEMENT LLC held 8.4764% of shares outstanding.
The other major institutional holder is ROSALIND ADVISORS, INC., with the holding of over 2.71 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.76 million and represent 7.5535% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . As of Dec 31, 2024 , the former fund manager holds about 2.33% shares in the company for having 1.07 shares of worth $0.31 million while later fund manager owns 568.75 shares of worth $0.16 million as of Dec 31, 2024 , which makes it owner of about 1.23% of company’s outstanding stock.
